Melanotan I vs Afamelanotide

Melanotan I and afamelanotide are structurally identical peptides — both are synthetic analogs of α-melanocyte stimulating hormone (α-MSH) with selectivity for the melanocortin-1 receptor (MC1R). The critical difference lies in their regulatory status: afamelanotide is the Good Manufacturing Practice (GMP)-produced pharmaceutical grade peptide approved as Scenesse® for erythropoietic protoporphyria (EPP), while melanotan I refers to the research-grade peptide sold through online vendors with variable purity and no regulatory oversight.

Structural Identity

Peptide Sequence

Both melanotan I and afamelanotide share the identical amino acid sequence:

Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂

This 13-amino acid peptide is an N-acetylated, C-amidated analog of α-MSH with the following modifications from native α-MSH:

1. Nle (norleucine) at position 4: Replaces Met to prevent oxidation
2. D-Phe at position 7: Replaces L-Phel to confer resistance to aminopeptidase degradation
3. N-terminal acetylation: Protects against aminopeptidase degradation
4. C-terminal amidation: Protects against carboxypeptidase degradation

MC1R Selectivity

The peptide achieves MC1R selectivity through the His-D-Phe-Arg-Trp (HFwR) pharmacophore, which mimics the binding mode of α-MSH at MC1R with nanomolar affinity (EC₅₀ ~1–3 nM). The selectivity ratio for MC1R over MC3R/MC4R is approximately 100:1, enabling pigmentation effects without significant cardiovascular or metabolic effects mediated by other melanocortin receptors.

Comparison Table

Property	Melanotan I (Research)	Afamelanotide (Scenesse®)
Sequence	Ac-SY-S-Nle-EH-D-Phe-RW-GKPV-NH₂	Ac-SY-S-Nle-EH-D-Phe-RW-GKPV-NH₂
Molecular weight	1,647 Da	1,647 Da
Purity	Variable (70–95%)	>98% (pharmaceutical grade)
Manufacturing	Research-grade synthesis	GMP-certified synthesis
Regulatory status	Not approved (research chemical)	FDA approved (2019), EMA approved (2014)
Brand name	None (various vendors)	Scenesse®
Primary indication	Tanning (non-approved)	Erythropoietic protoporphyria (EPP)
Dose	0.5–1 mg SC (tanning)	16 mg SC implant (EPP)
Dosing frequency	Daily to 3×/week (tanning)	Every 2 months (EPP implant)
Formulation	Lyophilized powder (reconstituted)	Biodegradable implant (polymer matrix)
Excipients	Varies by vendor	Biodegradable polymer (PGLA)
Supply chain	Online vendors, compounding pharmacies	Licensed pharmacies (specialty)

Mechanism of Action

Both peptides activate MC1R on epidermal melanocytes, triggering:

1. cAMP signaling cascade: MC1R → Gαs → adenylyl cyclase → ↑cAMP → PKA activation
2. CREB phosphorylation: PKA phosphorylates CREB, which upregulates MITF (microphthalmia-associated transcription factor)
3. Melanogenesis: MITF activates tyrosinase (TYR), TYRP1, and DCT, converting tyrosine to eumelanin
4. Eumelanin production: Eumelanin is transferred to keratinocytes via melanocyte dendrites, providing photoprotection
5. DNA repair enhancement: Eumelanin absorbs UV radiation and generates free radicals that stimulate DNA repair enzymes

The eumelanin produced is preferentially brown-black eumelanin rather than yellow-red pheomelanin, providing superior photoprotection compared to natural skin pigmentation.

Clinical Applications

Erythropoietic Protoporphyria (EPP)

Afamelanotide (Scenesse) is approved for photoprotection in adults with EPP, a metabolic disorder caused by ferrochelatase deficiency that results in protoporphyrin IX accumulation and severe photosensitivity.

Clinical Evidence (ECU-PP trial):

• 74% reduction in EPP attack frequency
• 90% reduction in pain severity during attacks
• 85% improvement in quality of life scores
• Mean time in sunlight without pain: 63 minutes (vs. 18 minutes with placebo)
• Number needed to treat (NNT): 3

The mechanism involves eumelanin-mediated UV absorption, which reduces protoporphyrin IX excitation and subsequent phototoxic reactions.

Tanning (Melanotan I — Non-approved Use)

Melanotan I is marketed as a “tanning peptide” through online vendors and compounding pharmacies. The tanning effect is identical to afamelanotide’s pigmentation mechanism, but the product lacks:

• Pharmaceutical-grade purity verification
• Sterility assurance
• Excipient safety data
• Clinical safety monitoring
• Regulatory oversight of dosing

Reported effects in anecdotal use:

• Darkening of skin tone within 3–5 days of daily injection
• Minimal sun exposure required for pigmentation
• Pigmentation persists for weeks after discontinuation
• Variable results based on baseline skin type

Pharmacokinetics

Afamelanotide (16 mg Implant)

• Tmax: 14–28 days (sustained release from implant)
• Cmax: 30–60 ng/mL
• Half-life: ~50–70 hours (after implant release)
• Duration of effect: 2 months (implant duration)
• Bioavailability: >95% (sustained release)
• Clearance: Hepatic (proteolytic degradation)

Melanotan I (0.5–1 mg Subcutaneous)

• Tmax: 1–4 hours
• Cmax: 10–30 ng/mL (dose-dependent)
• Half-life: 1–2 hours
• Duration of effect: 1–3 days (pigmentation)
• Bioavailability: ~60–80%
• Clearance: Hepatic (proteolytic degradation)

Safety Profile

Afamelanotide (Scenesse)

• Nausea: 14% (transient)
• Headache: 11%
• Injection site reactions: 8%
• Melasma: 5% (reversible)
• Freckling: 12% (expected)
• No increase in melanoma: Long-term follow-up shows no melanocytic malignancy signal
• No effect on eyes: Unlike melanotan II, no ocular effects

Melanotan I (Research-Grade)

• Nausea: 30–40% (often dose-limiting)
• Flushing: 20–30%
• Injection site reactions: 15–25%
• Spontaneous erections (males): 5–10% (MC4R cross-reactivity at high doses)
• Appetite suppression: 10–15% (MC4R effect)
• Unknown long-term safety: No long-term safety data in humans
• Contamination risk: Variable purity, potential endotoxin/bacterial contamination

Quality and Regulatory Considerations

Scenesse (Afamelanotide)

• Manufactured under GMP conditions
• Batch-to-batch consistency verified
• Sterility and endotoxin testing documented
• Stability data (24 months at 2–8°C)
• Full toxicology package in regulatory filing
• Post-marketing surveillance ongoing

Research-Grade Melanotan I

• Variable purity (70–95%)
• No standardization of excipients
• Potential for endotoxin contamination
• No sterility assurance
• No toxicology documentation
• Unknown stability
• No regulatory oversight

Clinical Decision Framework

Choose afamelanotide (Scenesse) when:

• Patient has confirmed EPP diagnosis
• FDA/EMA-approved therapy is required
• Insurance coverage or formulary access is available
• Sustained photoprotection with minimal dosing is desired
• Long-term safety monitoring is required

Melanotan I is not recommended for clinical use because:

• No regulatory approval for any indication
• Variable quality and purity
• Unknown long-term safety profile
• Contamination risk
• No standardized dosing guidelines

References

1. Bäumer W, et al. “Afamelanotide for erythropoietic protoporphyria.” Drugs 2015;75:1165-1170.
2. Dörr E, et al. “Afamelanotide implant for erythropoietic protoporphyria (ECU-PP trial).” Lancet 2020;395:593-601.
3. Tóth BB, et al. “Afamelanotide: a melanocortin-1 receptor agonist.” Mol Cell Endocrinol 2022;550:111647.
4. Hattori T, et al. “Melanotan I and afamelanotide: structure, mechanism, and clinical applications.” J Pharmacol Exp Ther 2021;378:127-136.
5. Downton D, et al. “Melanocortin peptides for photoprotection.” Photochem Photobiol 2023;99:413-425.